The infected individual had recently returned from a trip abroad.
Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results